Published in Blood on May 13, 2015
NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol (2015) 0.99
Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood (2016) 0.78
miR-146a and miR-155 Expression Levels in Acute Graft-Versus-Host Disease Incidence. Front Immunol (2016) 0.77
Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives. Front Immunol (2016) 0.77
GVHD and miR: good things in small packages. Blood (2015) 0.76
Cross-talk between macrophages and atrial myocytes in atrial fibrillation. Basic Res Cardiol (2016) 0.75
Inflammasome effects in GvHD. Oncotarget (2015) 0.75
Cathepsin E Deficiency Ameliorates Graft-versus-Host Disease and Modifies Dendritic Cell Motility. Front Immunol (2017) 0.75
The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease. Front Immunol (2016) 0.75
Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes. Front Immunol (2017) 0.75
Targeting Cytokines in GVHD Therapy. J Immunol Res Ther (2017) 0.75
Associations of interactions between NLRP3 SNPs and HLA mismatch with acute and extensive chronic graft-versus-host diseases. Sci Rep (2017) 0.75
CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity. Nat Chem Biol (2019) 0.75